Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans

Journal of Pharmaceutical Sciences

Volumn 91, Issue 9, 2002, Pages 1936-1947

  Grindel, J Michael ^a   Jaworski, Ted ^b   Piraner, Olga ^c   Emanuele, R Martin ^a   Balasubramanian, M ^d  

^a CytRx Corporation   (United States)

^b Pharmaceutical Product Development   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Innoconcepts   (United States)

Author keywords

Disposition; Renal clearance; Species comparison; Surfactant

Indexed keywords

CARBON 14; COPOLYMER; CYTOCHROME P450; POLOXAMER; SURFACTANT;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; DOG; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME INHIBITION; FECES ANALYSIS; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NONHUMAN; NORMAL HUMAN; RADIOACTIVITY; RAT; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; TOXICOKINETICS; URINARY EXCRETION;

EID: 0036771286     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10190     Document Type: Article

References (25)

1. Bentley PK, Davis SS, Johnson OL, Lowe KC, Washington C. 1989. Purification of pluronic F-68 for perfluorochemical emulsification. J Pharm Pharmacol 41:661-663.
2. Lowe KC, Furmidge BA, Thomas S. 1995. Haemolytic properties of pluronic surfactants and effects of purification. Artif Cells Blood Substit Immobil Biotechnol 23:135-139.
3. Smith CM, Hebbel RP, Tukey DP, Clawson CC, White JG, Vercellotti GM. 1987. Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. Blood 69:1631-1636.
4. Carr ME, Powers PL, Jones MR. 1991. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots. Thromb Haemost 66:565-568.
5. Carter C, Fisher TC, Hamai H, Johnson CS, Meiselman HJ, Nash GB, Stuart J. 1992. Haemorheological effects of a nonionic copolymer surfactant (poloxamer 188). Clin Hemorheol 12:109-120.
6. Hsu LL, Liu XW, Pierangeli S, Eckman JR, Aguayo SM, Jack D, Wick TM. 2000. Microcirculatory effects of blocking cell adhesion molecules in transgenic sickle cell mice. Blood 96:528a.
7. McKenna R, Cole E, MacLeod C, Emanuele M, Hunter R. 1989. The effects of RheothRx on platelet function and coagulation in man. Blood 74:411.
8. Grover FL, Kahn RS, Heron MW, Paton BC. 1973. A nonionic surfactant and blood viscosity. Arch Surg 106:307-310.
9. Toth K, Bogar L, Juricskay I, Keltai M, Yusuf S, Haywood LJ, Meiselman HJ. 1997. The effect of RheothRx injection on the hemorheological parameters in patients with acute myocardial infarction. Clin Hemorheol Microcirc 17:117-125.
10. Armstrong JK, Meiselman HJ, Fisher TC. 1995. Inhibition of red blood cell-induced platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx injection). Thromb Res 79:437-450.
11. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, Crawford R, Edwards S, Bustrack J, Emanuele M. 1997. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study. Blood 90:2041-2046.
12. Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz-Praga S, Grindel JM. 2001. Purified poloxamer 188 for the treatment of acute vaso-occlusive crisis of sickle cell disease: A double-blind, randomized, placebo-controlled study. JAMA 286:2099-2106.
13. Files BA, Ballas SK, Benjamin LJ, Wojtowicz-Praga S, Grindel JM. 1998. Multicenter trial of FLOCOR in patients with sickle cell disease and acute chest syndrome. Blood 92:30b.
14. Luchtman-Jones L, Files B, Ballas SK, Swerdlow P, Benjamin L, Hilliard L, Coates TD, Abboud M, Wojtowicz-Praga S, Grindel JM. 1999. Phase I study of FLOCOR in patients with acute chest syndrome of sickle cell disease. Blood 94:25b.
15. Plopper CG, Weir AJ, Morin D, Chang A, Philpot RM, Buckpitt AR. 1993. Postnatal changes in the expression and distribution of pulmonary cytochrome P450 monooxygenases during Clara cell differentiation in rabbits. Mol Pharmacol 44:51-61.
16. Ho JW, Moody DE. 1993. Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: Effect of psychoactive drugs on in vitro activity. Life Sci 52:21-28.
17. Chiba K, Manabe K, Kobayashi K, Takayama Y, Tani M, Ishizaki T. 1993. Development and preliminary application of a simple assay of S-mephenytoin 4′-hydroxylase activity in human liver rnicrosomes. Eur J Clin Pharmacol 44:559-562.
18. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. 1993. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204.
19. Duescher RJ, Elfarra AA. 1993. Determination of p-nitrophenol hydroxylase activity of rat liver microsomes by high-pressure liquid chromatography. Anal Biochem 212:311-314.
20. Zhang XJ, Thomas PE. 1996. Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metab Dispos 24:23-27.
21. Wang ZY, Stern IJ. 1975. Disposition in rats of a polyoxypropylene-polyoxyethylene copolymer used in plasma fractionation. Drug Metab Dispos 3:536-542.
22. Moghimi SM. 1999. Re-establishing the long circulatory behavior of poloxamine-coated particles after repeated intravenous administration: Applications in cancer drug delivery and imaging. Biochim Biophys Acta 472:399-403.
23. 14C]methacrylate nanoparticles after intravenous injection in rats. J Pharm Sci 73:1433-1437.
24. Clarke MSF, Prendergast MA, Terry AV Jr. 1999. Plasma membrane ordering agent pluronic F-68 (PF-68) reduces neurotransmitter uptake and release and produces learning and memory deficits in rats. Learn Mem 6:634-649.
25. Rodriguez SC, Singer EJ. 1996. Toxicology of polyoxyalkylene block copolymers. In: Nace VM, editor. Nonionic surfactants, Vol. 60; New York: Marcel Dekker. pp 211-241.